Clinical Trials Logo

Clinical Trial Summary

The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic disease and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.


Clinical Trial Description

Girls and young women with chronic condition are at higher risk for infections that can be prevented by vaccination. Human papillomavirus infection is very common, one of the three most common in the general population. A vaccine exists to significantly prevent this infection and its complications. In France, it is advisable to vaccinate girls and boys from the age of 9 years and as soon as possible in the case of acquired immunodeficiency since these patients are more likely to be suffering from cancer induced by the human papillomavirus. In France, the overall rate of vaccination coverage for girls is 21%, which is significantly lower than in several other industrialized countries. The vaccination coverage rate for human papillomavirus in patients with chronic diseases may be even lower. The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic condition and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06158802
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Sabrina DA COSTA, MD
Phone 1 44 49 48 04
Email sabrina.dacosta@aphp.fr
Status Recruiting
Phase
Start date January 23, 2024
Completion date July 2024